BJH - volume 13, issue 1, february 2022
A.M. Dekker , T. Feys MBA, MSc
Over the past few years, the exploration of the genomic and molecular landscape of acute myeloid leukaemia (AML), identification of mutations associated with the pathogenesis and understanding of the mechanisms of resistance to treatment has led to a significant shift in the treatment paradigms for patients with AML, resulting in improved clinical outcomes.1 Nevertheless, there is a persistent high need to improve survival and quality of life for patients with AML, especially with our aging population. During the Belgian Hematology Society post- ASH 2021 meeting Dr. Spilleboudt, Jules Bordet Institute, Brussels, gave a comprehensive summary of the highlights in advancements of AML treatment ranging from first line options, treatment in relapsed/refractory (R/R) patients, maintenance, and data on the burden of care in elderly patients.
(BELG J HEMATOL 2022;13(1):48-54)
Read more
Top
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.
